Nova Leap Health Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Chris Dobbin

Algemeen directeur

US$271.7k

Totale compensatie

Percentage CEO-salaris	22.2%
Dienstverband CEO	9yrs
Eigendom CEO	10.1%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	8.1yrs

Recente managementupdates

Should Shareholders Reconsider Nova Leap Health Corp.'s (CVE:NLH) CEO Compensation Package?

May 31

Recent updates

Nova Leap Health Corp.'s (CVE:NLH) 35% Share Price Surge Not Quite Adding Up

Oct 31

Risks Still Elevated At These Prices As Nova Leap Health Corp. (CVE:NLH) Shares Dive 27%

Sep 12

Nova Leap Health Corp.'s (CVE:NLH) 33% Price Boost Is Out Of Tune With Revenues

Jun 08

Should Shareholders Reconsider Nova Leap Health Corp.'s (CVE:NLH) CEO Compensation Package?

May 31

Analyse CEO-vergoeding

Hoe is Chris Dobbin's beloning veranderd ten opzichte van Nova Leap Health's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$462k
Jun 30 2024	n/a	n/a	US$126k
Mar 31 2024	n/a	n/a	-US$285k
Dec 31 2023	US$272k	US$60k	-US$1m
Sep 30 2023	n/a	n/a	-US$1m
Jun 30 2023	n/a	n/a	-US$902k
Mar 31 2023	n/a	n/a	-US$743k
Dec 31 2022	US$259k	US$59k	-US$836k
Sep 30 2022	n/a	n/a	-US$592k
Jun 30 2022	n/a	n/a	US$119k
Mar 31 2022	n/a	n/a	US$489k
Dec 31 2021	US$292k	US$63k	US$2m
Sep 30 2021	n/a	n/a	US$4m
Jun 30 2021	n/a	n/a	US$3m
Mar 31 2021	n/a	n/a	US$2m
Dec 31 2020	US$248k	US$63k	US$1m
Sep 30 2020	n/a	n/a	-US$278k
Jun 30 2020	n/a	n/a	-US$789k
Mar 31 2020	n/a	n/a	-US$313k
Dec 31 2019	US$235k	US$193k	-US$1m
Sep 30 2019	n/a	n/a	-US$730k
Jun 30 2019	n/a	n/a	-US$1m
Mar 31 2019	n/a	n/a	-US$922k
Dec 31 2018	US$249k	US$176k	-US$961k
Sep 30 2018	n/a	n/a	-US$1m
Jun 30 2018	n/a	n/a	-US$1m
Mar 31 2018	n/a	n/a	-US$1m
Dec 31 2017	US$95k	US$95k	-US$852k

Compensatie versus markt: De totale vergoeding ($USD 271.70K ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 167.81K ).

Compensatie versus inkomsten: De vergoeding van Chris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chris Dobbin (49 yo)

9yrs

Tenure

US$271,704

Compensatie

Mr. Christopher Donald Dobbin, also known as Chris, C.P.A., C.A., ICD D., serves as the Chief Executive Officer and President of Nova Leap Health Corp. and served as its Chief Financial Officer until Octob...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Dobbin	CEO, President & Director	9yrs	US$271.70k	10.09% CA$ 2.2m
Michael O'Keefe	Independent Director	9yrs	US$27.17k	2.58% CA$ 567.1k
Dana Hatfield	Independent Chairman of the Board	9yrs	US$45.28k	3.45% CA$ 759.1k
Marie Mullally	Independent Director	3.7yrs	US$22.64k	0.079% CA$ 17.3k
Anne Whelan	Independent Director	3.6yrs	US$22.64k	geen gegevens
Wayne Myles	Independent Director	7.2yrs	US$27.17k	4.32% CA$ 949.6k

8.1yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NLH wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).

Nova Leap Health Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Should Shareholders Reconsider Nova Leap Health Corp.'s (CVE:NLH) CEO Compensation Package?

Insufficient new directors

Nova Leap Health Corp., Annual General Meeting, Jun 07, 2024

Nova Leap Health Corp. Announces Change of Corporate Secretary

Independent Director recently bought CA$99k worth of stock

Independent Director recently bought CA$94k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.004 profit in 3Q 2023)

Nova Leap Health Corp.'s (CVE:NLH) 35% Share Price Surge Not Quite Adding Up

Risks Still Elevated At These Prices As Nova Leap Health Corp. (CVE:NLH) Shares Dive 27%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.003 (vs US$0.002 loss in 2Q 2023)

Nova Leap Health Corp.'s (CVE:NLH) 33% Price Boost Is Out Of Tune With Revenues

Should Shareholders Reconsider Nova Leap Health Corp.'s (CVE:NLH) CEO Compensation Package?

First quarter 2024 earnings released: EPS: US$0.005 (vs US$0.003 loss in 1Q 2023)

Insufficient new directors

Nova Leap Health Corp., Annual General Meeting, Jun 07, 2024

Nova Leap Health Corp. (CVE:NLH) Looks Just Right With A 28% Price Jump

Full year 2023 earnings released

Market Participants Recognise Nova Leap Health Corp.'s (CVE:NLH) Revenues

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0 in 2Q 2022)

Nova Leap Health Corp. Announces Impairment for the Second Quarter Ended June 30, 2023

Nova Leap Health Corp. to Report Q2, 2023 Results on Aug 10, 2023

Nova Leap Health Corp. Announces Change of Corporate Secretary

Nova Leap Health Corp. (CVE:NLH) Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Independent Director recently bought CA$99k worth of stock

First quarter 2023 earnings released: US$0.003 loss per share (vs US$0.005 loss in 1Q 2022)

Full year 2022 earnings released: US$0.01 loss per share (vs US$0.024 profit in FY 2021)

Does Nova Leap Health (CVE:NLH) Have A Healthy Balance Sheet?

Third quarter 2022 earnings released: EPS: US$0.007 (vs US$0.016 in 3Q 2021)

Third quarter 2022 earnings released: EPS: US$0.007 (vs US$0.016 in 3Q 2021)

Now 22% undervalued after recent price drop

Now 27% undervalued after recent price drop

Nova Leap Health Corp. announced that it has received CAD 2.385056 million in funding

Nova Leap Health Corp. announced that it expects to receive CAD 2.5 million in funding

Independent Director recently bought CA$94k worth of stock

Now 23% undervalued after recent price drop

Calculating The Intrinsic Value Of Nova Leap Health Corp. (CVE:NLH)

Second quarter 2022 earnings released: EPS: US$0 (vs US$0.005 in 2Q 2021)

Nova Leap Health (CVE:NLH) Is Carrying A Fair Bit Of Debt

First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.013 profit in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nova Leap Health Corp., Annual General Meeting, Apr 21, 2022

Independent Director recently bought CA$99k worth of stock

Nova Leap Health Corp. (TSXV:NLH) completed the acquisition of Home Care Business With Operations Located in Kentucky and Indiana.

Independent Chairman of the Board recently bought CA$53k worth of stock

Third quarter 2021 earnings released: EPS US$0.02 (vs US$0.007 in 3Q 2020)

Estimating The Intrinsic Value Of Nova Leap Health Corp. (CVE:NLH)

Nova Leap Health Corp. (TSXV:NLH) acquired Business assets of a home care services company located in Oklahoma.

Second quarter 2021 earnings released: EPS US$0.01 (vs US$0.012 loss in 2Q 2020)

Independent Director exercised options to buy CA$228k worth of stock.

Nova Leap Health Corp entered into an agreement to acquire Home care services company.

Nova Leap Health Corp. announced that it has received CAD 5.499999 million in funding

Nova Leap Health Corp. announced that it expects to receive CAD 1.999999 million in funding

First quarter 2021 earnings released: EPS US$0.01 (vs US$0.005 in 1Q 2020)

Nova Leap Health Corp. Appoints Marie Mullally to Board of Directors

Nova Leap Health (CVE:NLH) Strong Profits May Be Masking Some Underlying Issues

Full year 2020 earnings released: EPS US$0.02 (vs US$0.017 loss in FY 2019)

Revenue misses expectations

Nova Leap Health Corp., Annual General Meeting, Apr 29, 2021

New 90-day high: CA$0.87

New 90-day high: CA$0.58

Third quarter 2020 earnings released: EPS US$0.01

New 90-day high: CA$0.48

New 90-day high: CA$0.40

New 90-day high - CA$0.38

Earnings released

New 90-day low - CA$0.30

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd